Why Is Viridian Therapeutics Stock Sinking Monday?

Phase 3 TEPEZZA OBI trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate versus placebo over the 24-week controlled period. The result materially improves the drug's clinical profile and should bolster approval prospects and commercial upside for the developer, likely driving a meaningful positive reaction in the company's equity.

Analysis

Phase 3 TEPEZZA OBI trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate versus placebo over the 24-week controlled period. The result materially improves the drug's clinical profile and should bolster approval prospects and commercial upside for the developer, likely driving a meaningful positive reaction in the company's equity.